RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
NEW YORK, Jan. 09, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc. (NASDAQ:ELGX) securities between August 2, 2016 and November 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/endologix-inc. There is no cost or obligation to you.
According to the complaint, defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors.
If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/endologix-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
